About Acrux
Acrux is a company based in Melbourne (Australia) founded in 1998. Acrux offers products and services including Lidocaine and Prilocaine Cream, LENZETTO, EVAMIST, Dapsone 5% Gel, and Nitroglycerine 0.4% Ointment. Acrux operates in a competitive market with competitors including Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
- Headquarter Melbourne, Australia
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website acrux.com.au
- Social LinkedIn
- Legal Name Acrux Limited
- Annual Revenue$3.2 M (USD)290.25as on Jun 30, 2026
- Net Profit-$415.98 K (USD)89.84as on Jun 30, 2026
- EBITDA-$1.17 M (USD)80as on Jun 30, 2026
Products & Services of Acrux
Acrux offers a comprehensive portfolio of products and services, including Lidocaine and Prilocaine Cream, LENZETTO, EVAMIST, Dapsone 5% Gel, and Nitroglycerine 0.4% Ointment.
Cream for local anesthesia and pain relief applications
Topical product for hormone replacement purposes
Spray for estrogen delivery in treatments
Gel for acne and skin condition management
Ointment for angina and heart condition relief
IPO & Listings of Acrux
Acrux is a publicly listed company on the ASX with ticker symbol ACR in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Sep 2004
- Listed onASX: ACR
- Listed entityACRUX LIMITED
- Exchange sectorHealth technology
- ISINAU000000ACR3
- Share price0.01 AUD (+10% on the day) · 2026-10-09
- Market capitalisation6,728,195.00 AUD
- EPS (diluted, trailing year)-0.00 AUD
- Volume (last session)752,158
Financials of Acrux
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | 4.6M AUD | -604,000 AUD | -1.7M AUD |
| 2025 | 1.2M AUD | -6.0M AUD | -8.5M AUD |
| 2024 | 5.1M AUD | -5.8M AUD | -8.1M AUD |
| 2023 | 8.4M AUD | -764,000 AUD | -2.8M AUD |
| 2022 | 1.7M AUD | -9.8M AUD | -12.3M AUD |
Detailed financial statements for Acrux
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Acrux
Acrux operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| novonordisk.com | 1923 | Bagsvaerd, Denmark | $145,000 | 29,288 | Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| astrazeneca.com | 1913 | Cambridge, United Kingdom | – | 83,100 | Pharmaceutical and biologics products are developed and distributed worldwide. | |
| bausch.com | 1853 | Bridgewater, United States | – | 1,681 | Ophthalmic pharmaceuticals and instruments are developed for eye care. | |
| amgen.com | 1980 | Thousand Oaks, United States | – | 26,700 | Developer of pharmaceutical products for treating multiple diseases |
Detailed competitors of Acrux
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Acrux
The website of Acrux (acrux.com.au) receives about 3.7K visits a month and ranks #7,741,592 among all websites worldwide, #7,135 in Biotechnology and Pharmaceuticals.
- Monthly visits3.7K
▲ 57.6% vs previous month
- Unique visitors1.1K
per month
- Global rank#7,741,592
among all websites
- Category rank#7,135
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit1.3
- Average visit1 sec
- DevicesDesktop 7% · Mobile 93%
Websites whose visitors overlap most with Acrux. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lipa.com.au | 100% | 6.5K | #2,944,886 | View details | |
homart.com.au | homart.com.au | 96% | – | #3,826,166 | – |
| maynepharma.com | 95% | 18.6K | #918,677 | View details | |
| phebra.com | 90% | – | #2,430,553 | View details |
Latest news on Acrux
Complete news archive for Acrux
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Acrux
10 companies that operate in the same segment as Acrux (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Acrux
Acrux was founded in 1998.
Acrux is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Annual revenue of Acrux is $3.2M as on Jun 30, 2026.
Acrux was established in 1998 in Melbourne, Australia, as a pharmaceutical company specialising in drug development. Operations centre on the commercialisation of topical treatments via proprietary delivery methods. Existing products encompass Axiron, Ellavie, Evamist, and Lenzetto. The pipeline features ACR-065 for onchomycosis, alongside ACR-046 and ACR-048 for pain and inflammation, all at the preclinical stage.
Acrux's top competitors include Merck, Roivant Sciences and Amgen.
Acrux offers Lidocaine and Prilocaine Cream, LENZETTO, EVAMIST, Dapsone 5% Gel, and Nitroglycerine 0.4% Ointment.
Yes, Acrux is publicly traded on ASX under the ticker symbol ACR.
Acrux operates through Acrux Limited.